Literature DB >> 1680914

Anti-CD2 receptor antibodies activate the HIV long terminal repeat in T lymphocytes.

P Bressler1, G Pantaleo, A Demaria, A S Fauci.   

Abstract

The CD2 T lymphocyte glycoprotein surface molecule mediates both cell to cell adhesion and T cell activation, two processes that are involved in the spread of HIV infection. Treatment of chronically HIV-infected PBMC with anti-CD2 mAb has been shown to induce the expression of infectious virus from these cultures. In this study we investigated the mechanisms whereby anti-CD2 antibodies stimulate viral production. We demonstrate that treatment of transiently transfected T lymphocytes with anti-CD2 antibodies results in activation of the HIV long terminal repeat. Furthermore, CAT assays using mutated HIV long terminal repeat-CAT constructs and gel shift assays demonstrate that this activation is dependent on the NF-kappa B enhancer. These studies suggest that interaction of CD2 with its natural ligand, LFA-3, may play a role in regulation of HIV expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680914

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection.

Authors:  Y Takahashi; Y Tanaka; A Yamashita; Y Koyanagi; M Nakamura; N Yamamoto
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  1,25-Dihydroxyvitamin D3 upregulates functional CXCR4 human immunodeficiency virus type 1 coreceptors in U937 minus clones: NF-kappaB-independent enhancement of viral replication.

Authors:  P Biswas; M Mengozzi; B Mantelli; F Delfanti; A Brambilla; E Vicenzi; G Poli
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.

Authors:  D Weissman; G Poli; A Bousseau; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells.

Authors:  T M Niederman; J V Garcia; W R Hastings; S Luria; L Ratner
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  T-cell activation influences initial DNA synthesis of simian immunodeficiency virus in resting T lymphocytes from macaques.

Authors:  P S Polacino; H A Liang; E J Firpo; E A Clark
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes.

Authors:  B Asjö; D Cefai; P Debré; Y Dudoit; B Autran
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist.

Authors:  G Poli; A L Kinter; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

8.  Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants.

Authors:  P Bressler; K Brown; W Timmer; V Bours; U Siebenlist; A S Fauci
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.

Authors:  Maria Iglesias-Ussel; Claire Vandergeeten; Luigi Marchionni; Nicolas Chomont; Fabio Romerio
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

10.  Inference of surface membrane factors of HIV-1 infection through functional interaction networks.

Authors:  Samira Jaeger; Gokhan Ertaylan; David van Dijk; Ulf Leser; Peter Sloot
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.